<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02142049</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1124-CA</org_study_id>
    <nct_id>NCT02142049</nct_id>
  </id_info>
  <brief_title>Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and
      efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with
      relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b, open-label, non-randomized multicenter study conducted in 2 parts. Part
      1, will determine the MTD of the combination of ibrutinib, lenalidomide and DA-EPOCH-R in
      subjects with DLBCL.

      Ibrutinib will be administered at a fixed dose of 560 mg and lenalidomide will be
      dose-escalated. DA-EPOCH-R will be given at standard doses.

      For Part 2, the MTD determined in Part 1 will be the dose used for all subjects.

      The primary objective for Part 2 is to determine the ORR of ibrutinib and lenalidomide in
      combination with DA-EPOCH-R in subjects with ABC DLBCL (a subset of non-GCB DLBCL) as
      analyzed by gene expression profiling.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Dose-Limiting Toxicities as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year from first patient's first dose</time_frame>
    <description>Part-1: To determine the maximum tolerated dose (MTD) of the combination of ibrutinib and lenalidomide with dose adjusted EPOCH-R</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy</measure>
    <time_frame>1 year after last patient's first dose</time_frame>
    <description>Part 2 - Overall Response rate will be defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group Response Criteria for NHL as assessed by investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy</measure>
    <time_frame>1 year after first patient's first dose</time_frame>
    <description>Part-1: Overall Response rate (ORR) will defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group Response Criteria for NHL as assessed by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year after last patient's first dose</time_frame>
    <description>Part 2: The frequency (number and percentage) of treatment-emergent adverse events will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR), Progression Free Survival (PRF) and Overall Survival (OS) as a Measure of Efficacy</measure>
    <time_frame>1 year after firs patient's last dose</time_frame>
    <description>Part 2: DOR will be measured from the time by which the measurement criteria are met for CR or PR until the first date by which recurrent or progressive disease is objectively documented.
PFS will be measured as time from first study drug administration to disease progression or death from any cause.
OS will be measured from the time of first study drug administration until the date of death using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Diffuse Large B Cell Lymphoma Relapsed</condition>
  <condition>Diffuse Large B Cell Lymphoma Refractory</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg PO + DA-EPOCH-R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Level MTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim</description>
    <arm_group_label>Part 1: Dose Level 1</arm_group_label>
    <other_name>DA-EPOCH-R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: Dose Level 1</intervention_name>
    <description>Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim</description>
    <arm_group_label>Part 1: Dose Level 2</arm_group_label>
    <arm_group_label>Part 1: Dose Level 3</arm_group_label>
    <arm_group_label>Part 1: Dose Level 4</arm_group_label>
    <arm_group_label>Part 2: Dose Level MTD</arm_group_label>
    <other_name>Lenalidomide, DA-EPOCH-R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major inclusion criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2

          -  Pathologically confirmed relapsed/refractory DLBCL

          -  Subjects must have ≥1 measurable disease site on CT scan (≥ 1.5 cm in longest
             dimension).

          -  Adequate hepatic and renal function:

               -  AST or ALT ≤2.5 x ULN

               -  Serum Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥60 mL/min/1.73

               -  Bilirubin ≤1.5 x ULN

          -  Adequate hematologic function:

               -  ANC &gt;1,000 cells/mm3

               -  Platelets ≥75,000 cells/mm3

               -  Hemoglobin ≥8.0 g/dL

               -  Prothrombin time (PT) and activated partial thromboplastin time (aPTT) must be
                  ≤1.5 x the upper limit of the normal range (ULN)

          -  Must be registered into the Revlimid REMS™program and be willing to comply with the
             requirements of Revlimid REMS™.

        Major Exclusion Criteria:

          -  Known central nervous system lymphoma

          -  Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2
             weeks

          -  Radio- or toxin-immunoconjugates within 10 weeks

          -  Prior allogenetic stem cell (or other organ) transplant within 6 months or any
             evidence of active graft-versus-host disease or requirement for immunosuppressants
             within 28 days prior to first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta Neuenburg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics LLC an AbbVie Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SITE-1</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-2</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-10</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-3</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-5</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-6</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-4</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-8</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-9</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SITE-7</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>ABC</keyword>
  <keyword>GCB</keyword>
  <keyword>Primary Mediastinal B-cell lymphoma</keyword>
  <keyword>Pharmacyclics</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Rituximab</keyword>
  <keyword>EPOCH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

